Microsoft today announced that it has acquired Solair, a company that provides software companies can use to work with all of their Internet-connected devices. The software can run as a cloud service or on companies’ infrastructure. Solair also offers a hardware gateway that companies can use on their premises to interface between their devices and the cloud.
Volkswagen’s vast diesel emissions fraud went undetected for years. To finally expose it, an academic group attached portable emissions measurement systems to a diesel Passat and Jetta, then drove the cars round-trip from Seattle to Los Angeles to directly measure exhaust in real-world conditions and prove that VW had programmed the cars to disable the controls.
New software under development could do the same thing in just hours by monitoring vehicle data to infer problems with emissions controls without any need to sample the exhaust or directly detect that emissions controls weren’t engaged.
Kutxabank y sus antiguos socios industriales de Euskaltel, las dos grandes eléctricas Endesa e Iberdrola y el Grupo Mondragón, han contratado al bufete CMS Albiñana & Suárez de Lezo para dar la batalla en los tribunales a los dos fondos de inversión Trilantic e Investindustrial, con los que ‘partieron peras’ tras la colocación en bolsa del operador vasco.
We analyzed on-demand deal activity by sub-industry — including ride-hailing, shipping, and food delivery — to see which areas are still seeing deals and which ones slowed down after the rush in 2015.
As recently as mid-2015, investors were herding into on-demand, as they bought into the promise of disrupting established players in food delivery, home cleaning, transportation, and many other fields.
Google today announced that it has partnered with Fiat Chrysler to get dozens more self-driving cars in the wild.
The partnership was rumored to be in the works last week, and now it’s real.
“We’re planning to more than double our fleet with the initial addition of about 100 new 2017 Chrysler Pacifica Hybrid minivans, and we hope the first few will be on the road by the end of this year,” Google said in a Google+ post.
Companies in almost every industry are targeting the market for “connected” devices, from doorbells and thermostats sold by Nest Labs to something as advanced as automobile hardware and software that monitors your driving habits.
One Indiana-based company has steadily been building an infrastructure service that it hopes will help that market grow. CloudOne, located just northeast of Indianapolis in the city of Fishers, IN, offers large corporations the ability to develop applications used for tracking and analyzing data collected from connected devices, while storing and managing everything in a private cloud.
Last year’s shakeup and mea culpa at San Diego’s Acadia Pharmaceuticals (NASDAQ: ACAD) has paid off. The FDA said late today it has approved Acadia’s pimavanserin (Nuplazid), a treatment for psychosis associated with Parkinson’s disease.
112 personas han asistido a sesión informativa “Cómo hacer frente con éxito a los cambios tecnológicos y administrativos por la entrada en vigor de novedades legislativas y tecnológicas previstas por el Estado y la Unión Europea”.
Al final de este mensaje encontrarás un enlace para acceder a las siguientes presentaciones :
• Guía introductoria a la jornada.
• Presentación general de IZENPE.
• Presentación de METAPOSTA.
• Presentación sobre Factura Electrónica de IZENPE.
A group of biotech veterans have debuted today a new company, Homology Medicine, with a bold claim that their underlying science is a better version of the gene editing methods, such as CRISPR-Cas9, that have captured the attention of patients, doctors, and scientists looking to treat desperate diseases.
The claim is, for now, untested, as none of the work has been published. One of the company’s backers says Homology will publish some of its findings soon.
Biogen CEO George Scangos has spent the last several years focusing the company’s research efforts on drugs for tough-to-treat neurodegenerative diseases like Alzheimer’s and Parkinson’s. That made the Cambridge, MA-based company’s hemophilia drugs outliers, which is why perhaps it’s no surprise that today the company has announced plans to funnel those drugs into a separate, standalone business.
